RSS

Cablivi

The European Commission has granted marketing authorisation to Cablivi (caplacizumb) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP). more

News

Cablivi (caplacizumab) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of a rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) more

News